These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

341 related articles for article (PubMed ID: 34409431)

  • 1. Remdesivir and Mortality in Patients With Coronavirus Disease 2019.
    Diaz GA; Christensen AB; Pusch T; Goulet D; Chang SC; Grunkemeier GL; McKelvey PA; Robicsek A; French T; Parsons GT; Doherty G; Laurenson C; Roper R; Hadlock J; Cover CJ; Footer B; Robinson P; Micikas M; Marfori JE; Cronenweth C; Mukkamala Y; Mackiewicz J; Rai E; Matson MD; Davila J; Rueda J; Tipton R; Algren H; Ward BC; Malkoski S; Gluckman T; Tallman GB; Arguinchona H; Hammond TC; Standaert S; Christensen J; Echaiz JF; Choi R; McClung D; Pacifico A; Fee M; Sarafian F; Berrington WR; Goldman JD
    Clin Infect Dis; 2022 May; 74(10):1812-1820. PubMed ID: 34409431
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Remdesivir Treatment in Hospitalized Patients With Coronavirus Disease 2019 (COVID-19): A Comparative Analysis of In-hospital All-cause Mortality in a Large Multicenter Observational Cohort.
    Mozaffari E; Chandak A; Zhang Z; Liang S; Thrun M; Gottlieb RL; Kuritzkes DR; Sax PE; Wohl DA; Casciano R; Hodgkins P; Haubrich R
    Clin Infect Dis; 2022 Aug; 75(1):e450-e458. PubMed ID: 34596223
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative outcomes of combined corticosteroid and remdesivir therapy with corticosteroid monotherapy in ventilated COVID-19 patients.
    Mandadi S; Pulluru H; Annie F
    PLoS One; 2022; 17(2):e0264301. PubMed ID: 35196344
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term survival benefit of male and multimorbid COVID-19 patients with 5-day remdesivir treatment.
    Polivka L; Gajdacsi J; Fazekas L; Sebok S; Barczi E; Hidvegi E; Sutto Z; Dinya E; Maurovich-Horvat P; Szabo AJ; Merkely B; Müller V
    J Glob Health; 2022 Aug; 12():05031. PubMed ID: 36040909
    [TBL] [Abstract][Full Text] [Related]  

  • 5. COVID-19 and kidney transplantation: the impact of remdesivir on renal function and outcome - a retrospective cohort study.
    Elec F; Magnusson J; Elec A; Muntean A; Antal O; Moisoiu T; Cismaru C; Lupse M; Oltean M
    Int J Infect Dis; 2022 May; 118():247-253. PubMed ID: 35301103
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Remdesivir for Severe Coronavirus Disease 2019 (COVID-19) Versus a Cohort Receiving Standard of Care.
    Olender SA; Perez KK; Go AS; Balani B; Price-Haywood EG; Shah NS; Wang S; Walunas TL; Swaminathan S; Slim J; Chin B; De Wit S; Ali SM; Soriano Viladomiu A; Robinson P; Gottlieb RL; Tsang TYO; Lee IH; Hu H; Haubrich RH; Chokkalingam AP; Lin L; Zhong L; Bekele BN; Mera-Giler R; Phulpin C; Edgar H; Gallant J; Diaz-Cuervo H; Smith LE; Osinusi AO; Brainard DM; Bernardino JI;
    Clin Infect Dis; 2021 Dec; 73(11):e4166-e4174. PubMed ID: 32706859
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Remdesivir and corticosteroids in the treatment of hospitalized COVID-19 patients.
    Coelho L; Falcão F; Póvoa P; Viegas E; Martins AP; Carmo E; Fonseca C; Campos L; Mansinho K; Carmo I; Soares J; Solano M; Mendes D; Miranda AC; Carvalho A; Mirco A; Farinha H; Aldir I; Correia J
    Sci Rep; 2023 Mar; 13(1):4482. PubMed ID: 36934143
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of Remdesivir for Mildly to Moderately Ill Patients with COVID-19: A Single-Arm, Single-Center, Retrospective Study.
    Miyazaki M; Yanagida R; Nakashima A; Matsuo K; Moriwaki N; Uchiyama M; Yamada Y; Hirata H; Kushima H; Kinoshita Y; Ishii H; Imakyure O
    Medicina (Kaunas); 2022 Jul; 58(8):. PubMed ID: 36013474
    [No Abstract]   [Full Text] [Related]  

  • 9. An overview of the preclinical discovery and development of remdesivir for the treatment of coronavirus disease 2019 (COVID-19).
    Pagliano P; Sellitto C; Scarpati G; Ascione T; Conti V; Franci G; Piazza O; Filippelli A
    Expert Opin Drug Discov; 2022 Jan; 17(1):9-18. PubMed ID: 34412564
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Cost-Effectiveness Analysis of Remdesivir for the Treatment of Hospitalized Patients With COVID-19 in England and Wales.
    Rafia R; Martyn-St James M; Harnan S; Metry A; Hamilton J; Wailoo A
    Value Health; 2022 May; 25(5):761-769. PubMed ID: 35197225
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Risk factors for liver enzyme elevation with remdesivir use in the treatment of paediatric COVID-19.
    Jinda T; Mizuno S; Tatami S; Kasai M; Ishida T
    J Paediatr Child Health; 2024 Jul; 60(7):299-302. PubMed ID: 38818963
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Feasibility and safety of remdesivir in SARS-CoV2 infected renal transplant recipients: A retrospective cohort from a developing nation.
    Meshram HS; Kute VB; Patel H; Banerjee S; Navadiya V; Desai S; Rizvi SJ; Mishra V; Chauhan S
    Transpl Infect Dis; 2021 Aug; 23(4):e13629. PubMed ID: 33915006
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Remdesivir is a direct-acting antiviral that inhibits RNA-dependent RNA polymerase from severe acute respiratory syndrome coronavirus 2 with high potency.
    Gordon CJ; Tchesnokov EP; Woolner E; Perry JK; Feng JY; Porter DP; Götte M
    J Biol Chem; 2020 May; 295(20):6785-6797. PubMed ID: 32284326
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Compassionate use of remdesivir in children with COVID-19.
    Méndez-Echevarría A; Pérez-Martínez A; Gonzalez Del Valle L; Ara MF; Melendo S; Ruiz de Valbuena M; Vazquez-Martinez JL; Morales-Martínez A; Remesal A; Sándor-Bajusz KA; Cabañas F; Calvo C
    Eur J Pediatr; 2021 Apr; 180(4):1317-1322. PubMed ID: 33200304
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association of Remdesivir Treatment With Survival and Length of Hospital Stay Among US Veterans Hospitalized With COVID-19.
    Ohl ME; Miller DR; Lund BC; Kobayashi T; Richardson Miell K; Beck BF; Alexander B; Crothers K; Vaughan Sarrazin MS
    JAMA Netw Open; 2021 Jul; 4(7):e2114741. PubMed ID: 34264329
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Real-World Effectiveness of Remdesivir in Adults Hospitalized With Coronavirus Disease 2019 (COVID-19): A Retrospective, Multicenter Comparative Effectiveness Study.
    Garibaldi BT; Wang K; Robinson ML; Betz J; Caleb Alexander G; Andersen KM; Joseph CS; Mehta HB; Korwek K; Sands KE; Fisher AM; Bollinger RC; Xu Y
    Clin Infect Dis; 2022 Aug; 75(1):e516-e524. PubMed ID: 34910128
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Use of Remdesivir in children with COVID-19: report of an Italian multicenter study.
    Romani L; Roversi M; Bernardi S; Venturini E; Garazzino S; Donà D; Krzysztofiak A; Montagnani C; Funiciello E; Calò Carducci FI; Marabotto C; Castagnola E; Salvini F; Lancella L; Lo Vecchio A; Galli L; Castelli Gattinara G;
    Ital J Pediatr; 2024 Feb; 50(1):32. PubMed ID: 38413992
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Remdesivir MD Simulations Suggest a More Favourable Binding to SARS-CoV-2 RNA Dependent RNA Polymerase Mutant P323L Than Wild-Type.
    Mohammad A; Al-Mulla F; Wei DQ; Abubaker J
    Biomolecules; 2021 Jun; 11(7):. PubMed ID: 34206274
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Phase 3 Open-label, Randomized, Controlled Study to Evaluate the Efficacy and Safety of Intravenously Administered Ravulizumab Compared with Best Supportive Care in Patients with COVID-19 Severe Pneumonia, Acute Lung Injury, or Acute Respiratory Distress Syndrome: A structured summary of a study protocol for a randomised controlled trial.
    Smith K; Pace A; Ortiz S; Kazani S; Rottinghaus S
    Trials; 2020 Jul; 21(1):639. PubMed ID: 32660611
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Off-Target
    Xu Y; Barauskas O; Kim C; Babusis D; Murakami E; Kornyeyev D; Lee G; Stepan G; Perron M; Bannister R; Schultz BE; Sakowicz R; Porter D; Cihlar T; Feng JY
    Antimicrob Agents Chemother; 2021 Jan; 65(2):. PubMed ID: 33229429
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.